micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved



Similar documents
Micro RNAs: potentielle Biomarker für das. Blutspenderscreening

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

The RNA strategy. RNA as a tool and target in human disease diagnosis and therapy.

OriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation

A role of microrna in the regulation of telomerase? Yuan Ming Yeh, Pei Rong Huang, and Tzu Chien V. Wang

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS

PART 3.3: MicroRNA and Cancer

March 19, Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

The world of non-coding RNA. Espen Enerly

A 70-year old Man with Pleural Effusion

Lezioni Dipartimento di Oncologia Farmacologia Molecolare. RNA interference. Giovanna Damia 29 maggio 2006

Human Genome Organization: An Update. Genome Organization: An Update

LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

School of Nursing. Presented by Yvette Conley, PhD

Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi

Special report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006

FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM. ChromoPlex 1 Dual Detection for BOND

CANADIAN RULE BASED CLASSIFICATION SYSTEM (IVDD) Life Sciences British Columbia NRC-Industry Research Assistance Program

岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹

Microarray Technology

Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy

Outline. MicroRNA Bioinformatics. microrna biogenesis. short non-coding RNAs not considered in this lecture. ! Introduction

OBJECTIVES By the end of this segment, the community participant will be able to:

How Cancer Begins???????? Chithra Manikandan Nov 2009

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger

Biofocus Molecular Diagnostic Panel

mirnaselect pep-mir Cloning and Expression Vector

Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)

CHAPTER 2: UNDERSTANDING CANCER

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

Common Cancers & Hereditary Syndromes

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Blood-Based Cancer Diagnostics

How To Get A Cell Print

Recombinant DNA and Biotechnology

Types of Cancers [-oma growth ]!

Normal values of IGF1 and IGFBP3. Kučera R., Vrzalová J., Fuchsová R., Topolčan O., Tichopád A.

Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes

Medical Informatics II

DNA Fingerprinting. Unless they are identical twins, individuals have unique DNA

New strategies in anticancer therapy

ncounter Leukemia Fusion Gene Expression Assay Molecules That Count Product Highlights ncounter Leukemia Fusion Gene Expression Assay Overview

PNA BRAF Mutation Detection Kit

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

PATHOLOGY. HercepTestTM. Product Information

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

INTERPRETATION INFORMATION SHEET

Comparative genomic hybridization Because arrays are more than just a tool for expression analysis

A Genetic Analysis of Rheumatoid Arthritis

RNAi Shooting the Messenger!

Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs)

Personalized Treatment for Malignant Mesothelioma

How Does a Doctor Test for AIDS?

Biomedical Engineering for Global Health. Lecture Thirteen

How can we generate economic value from personalized medicine and big data analysis?

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

MicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma

Profiling of non-coding RNA classes Gunter Meister

Contents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer

Uses of Flow Cytometry

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

DETERMINATION OF HER2 STATUS IN BREAST CANCER PATIENTS BY TWO METHODS: REAL-TIME QUANTITATIVE PCR (QPCR) AND IMMUNOENZIMATIC ASSAY (EIA)

Relative Quantification of mirna Target mrnas by Real-Time qpcr. 1 Introduction. Gene Expression Application Note No. 4

Progress and Prospects in Ovarian Cancer Screening and Prevention

Analysis of gene expression data. Ulf Leser and Philippe Thomas

The Diagnosis of Cancer in the Pathology Laboratory

DP419 RNAsimple Total RNA Kit. RNAprep pure Series. DP501 mircute mirna Isolation Kit. DP438 MagGene Viral DNA / RNA Kit. DP405 TRNzol Reagent

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

ALLEN Mouse Brain Atlas

Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes

Digital Pathology Image Analysis with Definiens


Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

If you were diagnosed with cancer today, what would your chances of survival be?

Measuring gene expression (Microarrays) Ulf Leser

ab StayBlue/AP Plus Stain Kit Instructions for Use An immunohistochemical chromogen substrate for staining tissue sections

HER2 FISH pharmdx. Assay Kit

Molecular Diagnostics in Thyroid Cancer

Fulfilling the Promise

HER2 Testing in Breast Cancer

Targeted Therapy What the Surgeon Needs to Know

Early Detection Research Network: Validation Infrastructure. Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention

Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3

Targeted Therapies in Lung Cancer

Transcription:

microrna

2

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative regulators of gene expression mirnaexpression profile is tissue specific 3

mirna functions Regulate 30% of coded genes Bring about translation inhibition and mrna cleavage A part of the mirnamatches the target mrna The greater the degree of complimentarity with the target mrna, greater is the probability of mrna degradation 4

Diversity of mirna functions Development Timing Cell proliferation Stem cell Cell death DNA methylation and chromatin formation Diseases Cancer Diabetes Cholesterol biosynthesis Nervous system disorders Autoimmune diseases Metabolic diseases 5

micrornas micrornas Tumourigenesis Metabolism Viral Infection Aging and Apoptosis Development / Differentiation 6

mirna and Cancer Majority of mirnagenes are located in cancer associated regions and chromosome fragile sites Indicate a differential expression pattern in normal and tumor tissues mirnadisplay tissue and cell lineage specificity Altered mirnaexpression pattern can serve as markers for Tumor diagnosis Disease prognosis Therapeutic response prediction Cancer of unknown primary http://dx.doi.org/10.1038/nature10888 7

micrornas: Oncogene / Tumor Suppressor Oncogenic mirnas: Tumor Suppressor mir-17-92 Tumor suppressor mirnas: Pten Tumor let-7 Oncogene Ras Normal cell 8

mirnas: Oncogene / Tumor Suppressor Cancer Type Human microrna Potential Function Breast Cancer mir-21, mir-125b; mir126, mir-206, mir-335 OncomiR; Metastasis Suppressor Colon Cancer mir-21; mir-34a OncomiR; Tumor Suppressor Lung Cancer mir-21, mir17-92 cluster, mir-106b/93/25 cluster; Let-7a, mir-143, mir-145 OncomiR; Tumor Suppressor Pancreatic Cancer mir-196a, mir196b OncomiR Prostate Cancer Ovarian Cancer Hepatocellular Carcinoma Thyroid Cancer mir-21, mir-15/16; mir145, mir-146, mir-330, mir205 mir-141, mir-200a/b/c; mir-199a/b, mir-140, mir-145, mir-204, mir125a/b, mir-21, mir-224, mir34a, mir221, mir-222, mir-106, mir-303; mir26a/b, let-7g, mir-122, mir-422b, mir-145, mir-199 mir-146, mir-221, mir222, mir-181b, mir-155, mir224 OncomiR; Tumor Suppressor OncomiR; Tumor Suppressor OncomiR; Tumor Suppressor; Metastasis OncomiR 9

mirna & Cancer of Unknown Primary (CUP) Malignant cancers whose origins cannot be identified based on Clinical history Complete physical examination Routine laboratory tests Imaging and radio metabolic techniques Histological analysis Accounts for 3-5% of all cancers The prognosis of patients with CUP is poor with a median survival of 4-12 months 10

mirna & Cancer of Unknown Primary (CUP) Present treatment is based on consideration for the cell type This leads to reduced antineoplastic efficacy and poor outcome. mirnabased classification gave 90% accuracy in classifying cancers of unknown primary Classification based on differential expression of mirnathat correlated with cancer type, stage and clinicopathological variables Provides superior classification of CUP when compared with classification based on mrna 11

mirnas as diagnostic markers Utilizing a signature of altered mirna expression to differentiate cancer tissue from normal tissue Profiling circulating blood or tumor derived exosomal mirnas, surpassing the invasive procedures to aid in early detection of cancers MicroRNAs in Cancer Diagnosis Use of mirna based classifier to identify tissue of origin for cancers of unknown primaries Distinguishing tumor subtypes using a panel of mirnas that show differential expression within one cancer type Study SNPs in the mirna genes, mirna binding sites in the target mrna genes or in the mirna processing/ machinery pathway genes to predict cancer predisposition 12 MicroRNAs: tools for cancer diagnostics. Gut 2009;58:1546 1554. doi:10.1136/gut.2009.179531

mirna Analysis Microarray qrt-pcr RNase protection assay Northern blot 13

mirnas in Situ Hybridization Larger scale analysis of mirnasis required for fully understanding their biological functions within disease setting. FFPE tissue samples are invaluable source for this study. Study the macroscopic distribution and cellular localization of mirnasin a heterogeneous cell population. Several technique problems in mirnasin situ hybridization: RNA integrity, lower concentration, very short RNA nucleotides, protection from associated proteins and cellular structure. 14

micrornas are Stable in FFPE Tissues Year Xi et al. 2007 RNA 13:1-7 Li et al. BMC Biotechnol. 2007; 7: 36. 2 15

micrornas are Stable in FFPE Tissues Year Xi et al. 2007 RNA 13:1-7 Li et al. BMC Biotechnol. 2007; 7: 36. 2 16

Workflow for MicroRNA Detection Loading Slides Deparaffinization and Pretreatment Adding mirna Probes BioGenex mirna Detection Systems mir-21 mir-21 & p53 Probes labeled with BioGenex 5 -Fluorescein 17

mirna Analysis - ISH mirna sare well preserved in FFPE and frozen samples Can be exploited to understand their role in diseases Allows to study macroscopic distribution and cellular localization of mirnain a heterogeneous population 18

mirna in-situ hybridization work flow Dewaxing Proteinase K treatment Labeled mirna Probe incubation Stringent Buffer wash Chromogen Secondary antibody (Polymer HRP) Anti-fluorescein antibody Peroxide Block and Power Block Hematoxylin counter stain Clearing and Mounting 19

mirna as Therapeutic Targets OncomiRscan act as targets for down regulation Can be targeted by anti-sense nucleotides to bring about anti-cancer effect Timor suppressive mirnascan be upregulated to inhibit tumor progression 20

Biogenex mirna probes I A C A. Has-miR-1 B. Has-miR-21 C. Has-miR-146a B A C A. Has-miR-145 B. Has-miR-205 C. mir-145 mutant B 21

Biogenex mirna probes II A C A. Has-miR-328 B. SnRNA U6 C. Has-miR-221 B A A. Has-miR-146 +anti-p53 B. Has-miR-222 B 22

One Step ISH detection Kit BioGenex has launched in-situ detection of micrornas in FFPE tissues on fully automated Xmatrx system. It offers the following advantages: Complete kit with all reagents needed, we also offer positive (snrnau6 probe) and negative (Scramble sequence) probes Biotin-free system to avoid endogenous biotin activity. Poly-HRP detection system provides higher sensitivity. Can be combined with IHC to co-detect mirna and protein biomarkers. 23

24 One Step ISH detection Kit

Thank You Please visit www.biogenex.com for more details on our product portfolio 25